Methods for direct fluorescent antibody virus detection in liquids
View Patent ↗The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.
1. A method, comprising:
a) providing;
i) a suspension comprising a biological sample, wherein said sample is suspected of comprising at least two viral antigens, wherein said suspension further comprises a staining reagent selected from the group consisting of Evans blue, propidium iodide, acridine orange and combinations thereof;
ii) at least two fluorescently labeled antibodies, wherein each of said at least two viral antigens is capable of directly binding to one of said at least two said fluorescently labeled antibodies, wherein said antibodies are differentially labeled, and wherein one of said at least two said fluorescently labeled antibodies has specific affinity for an influenza A viral antigen and the other has specific affinity for an influenza B viral antigen;
b) incubating said suspension with said fluorescently labeled antibodies under conditions such that each of said fluorescently labeled antibodies directly binds one of said viral antigens, thereby forming at least one labeled antigen-antibody complex; and
c) detecting said at least one labeled antigen-labeled antibody complex within said suspension by identifying at least one fluorescently labeled antibody, thereby identifying at least one of said at least two viral antigens.
2. The method of claim 1 , wherein said fluorescently labeled antibodies comprise monoclonal antibodies.
3. The method of claim 2 , wherein said fluorescently labeled influenza A monoclonal antibody comprises a R-phycoerythrin fluorescent label.
4. The method of claim 2 , wherein said fluorescently labeled influenza B monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
5. A method, comprising:
a) providing;
i) a suspension comprising a biological sample, wherein said sample is suspected of comprising at least two viral antigens, wherein said suspension further comprises a staining reagent selected from the group consisting of Evans blue, propidium iodide, acridine orange and combinations thereof;
ii) at least two fluorescently labeled antibodies, wherein each of said at least two viral antigens is capable of directly binding to one of said at least two said fluorescently labeled antibodies, wherein said antibodies are differentially labeled, and wherein one of said at least two said fluorescently labeled antibodies has specific affinity for respiratory syncytial viral antigen and the other has specific affinity for a metapneumovirus viral antigen;
b) incubating said suspension with said fluorescently labeled antibodies under conditions such that each of said fluorescently labeled antibodies directly binds one of said viral antigens, thereby forming at least one labeled antigen-antibody complex; and
c) detecting said at least one labeled antigen-labeled antibody complex within said suspension by identifying at least one fluorescently labeled antibody, thereby identifying at least one of said at least two viral antigens.
6. The method of claim 5 , wherein said fluorescently labeled antibodies comprise monoclonal antibodies.
7. The method of claim 6 , wherein said fluorescently labeled monoclonal respiratory syncytial virus antibody comprises a R-phycoerythrin fluorescent label.
8. The method of claim 6 , wherein said fluorescently labeled metapneumovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
9. A method, comprising:
a) providing;
i) a suspension comprising a biological sample, wherein said sample is suspected of comprising at least two viral antigens, wherein said suspension further comprises a staining reagent selected from the group consisting of Evans blue, propidium iodide, acridine orange and combinations thereof;
ii) at least two fluorescently labeled antibodies, wherein each of said at least two viral antigens is capable of directly binding to one of said at least two said fluorescently labeled antibodies, wherein said antibodies are differentially labeled, and wherein one of said at least two said fluorescently labeled antibodies has specific affinity for adenovirus viral antigen and the other has specific affinity for a parainfluenza viral antigen;
b) incubating said suspension with said fluorescently labeled antibodies under conditions such that each of said fluorescently labeled antibodies directly binds one of said viral antigens, thereby forming at least one labeled antigen-antibody complex; and
c) detecting said at least one labeled antigen-labeled antibody complex within said suspension by identifying at least one fluorescently labeled antibody, thereby identifying at least one of said at least two viral antigens.
10. The method of claim 9 , wherein said fluorescently labeled antibodies comprise monoclonal antibodies.
11. The method of claim 10 , wherein said fluorescently labeled adenovirus monoclonal antibody comprises a fluorescein isothiocyanate fluorescent label.
12. The method of claim 10 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a R-phycoerythrin fluorescent label.
13. The method of claim 10 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 1 viral antigen.
14. The method of claim 10 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 2 viral antigen.
15. The method of claim 10 , wherein said fluorescently labeled parainfluenza monoclonal antibody comprises a specific affinity for said parainfluenza 3 viral antigen.
16. A method, comprising:
a) incubating a suspension comprising a biological sample, and a detergent, wherein said sample is suspected of comprising at least two viral antigens, with at least two differentially fluorescently labeled antibodies, wherein each of said at least two viral antigens is capable of directly binding to one of said at least two said fluorescently labeled antibodies, wherein at least one labeled antigent-antibody complex is formed; and
b) detecting said at least one labeled antigent-labeled antibody complex within said suspension by identifying at least one of said differentially fluorescently labeled antibodies, thereby identifying at least one of said at least two viral antigens.
17. The method of claim 16 , wherein said fluorescently labeled antibodies comprise monoclonal antibodies.
18. The method of claim 16 , wherein at least one of said fluorescently labeled antibodies comprise specific affinity for respiratory syncytial viral antigen.
19. The method of claim 16 , wherein at least one of said fluorescently labeled antibodies comprise a specific affinity for influenza A viral antigen.
20. The method of claim 16 , wherein at least one of said fluorescently labeled antibodies comprise a specific affinity for influenza B viral antigen.
21. The method of claim 16 , wherein at least one of said fluorescently labeled antibodies comprise a specific affinity for said adenovirus viral antigen.
22. The method of claim 16 , wherein at least one of said fluorescently labeled antibodies comprise a specific affinity for parainfluenza viral antigen.
23. The method of claim 16 , wherein at least one of said fluorescently labeled antibodies comprises a specific affinity for metapneumovirus viral antigen.
24. The method of claim 16 , wherein said detergent is sapogenin.